Key Findings:  Results provide critical preclinical evidence supporting treatment of epilepsy and autistic-like behaviors linked to DS with CBD. The authors also introduce antagonism of GPR55 as a potential therapeutic approach by illustrating its beneficial effects in DS mice. This study provides essential preclinical evidence needed to build a sound scientific basis for increased medicinal use of CBD.
Type of Study:  Animal Study
Study Result:  Positive
Study Location(s):  United States
Year of Pub:  2017
Cannabinoids Studied:  Cannabidiol (CBD)
Phytocannabinoid Source:  Not Applicable
Chemotype:  Chemotype III
Receptors Studied:  GPCR 55